Granules India Completes Acquisition Of Swiss Peptide Maker Senn Chemicals

Granules India on Thursday said it has completed the acquisition of Senn Chemicals AG, a Switzerland-based contract development and manufacturing organisation specialising in peptide therapeutics. 

The deal, which marks Granules' foray into the high-growth peptide segment, was executed through its wholly owned subsidiary, Granules Peptides Pvt. Ltd.

The acquisition was made at 20 million Swiss Francs which is approximately Rs 19 billion, according to a report in Business Standard. 

The deal enables the Hyderabad-based company to accelerate the development and production of GLP-1 drugs and other peptide-based ingredients for treating diabetes, obesity, and related conditions. The companies have already begun collaborating on these initiatives.

In February 2025, Granules signed an agreement to acquire 100% equity in Dielsdorf-based Senn Chemicals from the founding Senn family. With 60 years of experience, Senn Chemicals is known for its expertise in both liquid-phase and solid-phase peptide synthesis and serves the pharmaceutical, cosmetic, amino acid derivative, and theragnostic industries. 

Granules plans to maintain the Senn brand and its Dielsdorf operations, focusing on preserving its scientific strengths and client relationships.

The acquisition is part of Granules’ broader strategy to reposition itself as a science- and innovation-led organisation.

At 1402 IST, shares of Granules India were at ₹447.95, up 4% from Wednesday’s close.